Botox vs Xeomin: The "Naked Toxin" Compared (2026)

*FDA status: Botox Cosmetic is FDA-approved for frown (glabellar) lines, crow's feet, and forehead lines. Xeomin's cosmetic approval covers frown lines only, so using it for crow's feet or the forehead is off-label but common. Both also carry FDA approvals for several medical conditions. This is educational content, not medical advice.*

If you have researched anti-wrinkle injections, you have almost certainly compared Botox to Xeomin. They belong to the same family of muscle-relaxing neuromodulators, they treat the same expression lines, and in skilled hands they produce results most patients cannot tell apart. The headline difference is what Xeomin leaves out. Merz Aesthetics markets it as the naked toxin because it is purified down to the active botulinum molecule, with the surrounding complexing proteins removed. Whether that purity translates into a meaningful advantage for you depends less on marketing and more on how often you get treated, which areas you want addressed, and who is holding the needle.

This guide breaks down what the two products share, where they genuinely diverge on formulation, onset, dosing, and approvals, who tends to do better on one versus the other, how their safety profiles compare, and what actually drives the price. The goal is an honest, evidence-anchored comparison, not a verdict that one brand wins. Botulinum toxin outcomes are driven far more by injector technique and dosing judgment than by which vial is on the tray.

Botox and Xeomin at a glance

Botox, made by Allergan (now part of AbbVie), is onabotulinumtoxinA. It launched cosmetically in the United States in 2002 and remains the most recognized and most studied neuromodulator in the world. Xeomin, made by Merz Aesthetics, is incobotulinumtoxinA and reached the US cosmetic market in 2011. Both are botulinum toxin type A, both are injected into specific facial muscles, and both work by temporarily blocking the nerve signals that tell those muscles to contract. Relax the muscle and the overlying skin creases soften.

The practical takeaways are simple. Their wrinkle-smoothing results are clinically comparable. Their duration is the same, roughly 3 to 4 months. Their dosing is close to one to one in everyday practice, unlike Dysport, which uses a different unit scale. The real points of difference are Xeomin's protein-free formulation, Botox's broader set of FDA-approved cosmetic areas and longer safety record, and how each is priced. The table below lays the key attributes side by side.

What Botox and Xeomin have in common

Far more unites these two products than separates them. Both are purified botulinum toxin type A, the same neurotoxin produced by Clostridium botulinum bacteria and dosed in tiny, controlled amounts. Both work by the same mechanism: they block the release of acetylcholine at the neuromuscular junction, which stops the treated muscle from fully contracting. Over the following days, the dynamic lines created by that muscle, such as frown lines between the brows, horizontal forehead lines, and crow's feet, gradually soften.

Both are temporary and fully reversible as the nerve endings regenerate, with effects lasting about 3 to 4 months before movement returns and a repeat treatment is needed. Both are quick in-office injections with no true downtime, so patients typically return to normal activities the same day. Both share the same core side effect profile and the same class-wide FDA boxed warning about the theoretical spread of toxin effects beyond the injection site, an event that is very rare at cosmetic doses.

And in head-to-head clinical use, both deliver natural, comparable smoothing when they are dosed and placed correctly. Published reviews consistently find onabotulinumtoxinA and incobotulinumtoxinA comparable in cosmetic efficacy. For the average person treating frown lines, the everyday experience of the two products is nearly identical, which is exactly why the marketing leans so hard on the one formulation difference.

The key differences: formulation, onset, dosing, and FDA approvals

The differences are real but narrower than marketing suggests. Formulation is the headline. Botox is a roughly 900 kilodalton complex in which the active toxin is bound to accessory complexing proteins. Xeomin strips those proteins away, leaving only the 150 kilodalton active molecule plus human albumin and sucrose, three ingredients in total. This is the naked toxin claim, and it is accurate as a description of what is in the vial.

Onset is broadly similar, though the Xeomin label lists a median onset of effect around seven days, while many patients and injectors report Botox beginning to work within three to five days. Individual response varies more than the brand does, so onset is not a reliable way to pick between them.

Dosing is close to one to one in routine cosmetic practice, so 20 units of one is generally treated as equivalent to 20 units of the other for a given area. Importantly, the FDA states that units of different botulinum toxin products are not interchangeable, and one laboratory study found incobotulinumtoxinA showed roughly 54 percent of the biological activity of label-stated onabotulinumtoxinA units. In the clinic, these nuances are managed by your injector adjusting the dose to your muscles rather than by any fixed conversion.

FDA approvals differ, and this is a genuine honesty point. Botox Cosmetic is approved for frown lines, crow's feet, and forehead lines. Xeomin's cosmetic approval covers frown lines only, so treating crow's feet or the forehead with it is off-label, though this is widely and safely done in practice. Xeomin also stores at room temperature before reconstitution, a minor handling convenience for clinics that does not affect your result.

Which one for whom: matching the toxin to the patient

No single product is right for everyone, and a good injector chooses based on your goals rather than habit. Xeomin's purified formulation is most relevant for people who receive frequent, high-dose treatment, for example those treating large areas or using toxin for medical conditions in addition to cosmetics. Because complexing proteins are the part of the formulation most associated with immune recognition, removing them lowers the theoretical risk of forming neutralizing antibodies that can make treatment less effective over time. This resistance is uncommon overall, so for someone getting a modest frown-line treatment two or three times a year, the practical benefit is small.

Botox tends to suit people who value the longest track record and the widest set of on-label cosmetic areas, and those who have had reliably good results with it and see no reason to switch. Some injectors also favor Botox's familiarity when treating delicate zones, simply because its behavior is the most extensively documented.

Patients who have previously stopped responding to Botox, or who are specifically concerned about building resistance, are often steered toward Xeomin for its protein-free profile. Anyone who is pregnant, breastfeeding, or living with a neuromuscular disorder such as myasthenia gravis, Lambert-Eaton syndrome, or ALS should avoid both until cleared by a physician, since these cautions apply to the entire toxin class and not to one brand.

Safety and side effects of both

Because they are the same class of drug, Botox and Xeomin share essentially the same safety profile. The most common side effects are mild and temporary: redness, swelling, or bruising at the injection sites, headache, and a heavy or tight sensation as the muscle relaxes. These usually settle within a few days.

Less common but more bothersome effects come down to placement rather than product. If toxin diffuses into a muscle that was not the target, it can cause a drooping eyelid or brow, an uneven smile, or a temporary asymmetry. Treatment near the eyes can occasionally cause dry eye or excess tearing. These effects are temporary and resolve as the toxin wears off, but they are the clearest reason to choose an experienced injector who understands facial anatomy, since technique, not brand, drives them.

Both products carry the botulinum toxin class boxed warning about effects potentially spreading beyond the injection site, which can in theory cause swallowing or breathing difficulty. This is associated with large therapeutic doses and has not been an issue at standard cosmetic doses. Serious allergic reactions are rare. People who are pregnant or breastfeeding, or who have certain neuromuscular disorders, should not use either product. Report any trouble swallowing, breathing, or speaking after treatment to a doctor promptly.

What each costs and why per-unit price misleads

Cost is where the comparison gets muddled. Because Botox and Xeomin dose close to one to one, their per-unit prices are directly comparable, unlike the Dysport comparison, where a lower per-unit number simply reflects a different scale. In many markets Xeomin is priced slightly lower per unit than Botox, which is part of its appeal, but the gap is often modest and varies widely by clinic, city, and provider promotions.

Real prices depend on how many units you need, which is driven by your muscle strength and the areas treated, not just the sticker price per unit. A frown-line treatment might use around 20 units, while treating the forehead and crow's feet together uses considerably more. Some clinics charge per area rather than per unit, which can hide the underlying dose. We do not quote fixed prices, because they vary by provider, region, number of units, and current offers, and a low per-unit headline can mask a higher total.

The honest way to compare cost is by the total for your specific treatment plan with a specific injector, and by the value of the result, not by the cheapest advertised unit. A slightly higher price with a skilled injector who uses the right dose is usually the better value than a bargain unit price that leaves you under-treated or unevenly done.

How to choose: the injector matters more than the brand

If you take one thing from this comparison, make it this: the person injecting matters far more than which of these two vials they use. Both are excellent, well-studied botulinum toxin type A products, and in expert hands either produces a natural, balanced result. Technique, dosing judgment, and knowledge of your facial anatomy determine whether you look refreshed or overdone, far more than the brand name on the box.

Choose Xeomin if you get frequent or high-dose treatment and want the protein-free formulation, if resistance is a concern for you, or if it is priced better where you go. Choose Botox if you value the longest track record and the widest on-label cosmetic coverage, or if it has simply worked well for you before. For most people treating frown lines a few times a year, the two are effectively interchangeable, and the decision comes down to your injector's recommendation and the total cost.

Start by finding a qualified, licensed injector who treats your target areas regularly, then discuss which product fits your goals, your history, and your budget. A short consultation will tell you far more than any brand comparison, because the right answer is specific to your face.